Orion Oyj
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORINY research report →
Companywww.orion.fi
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services.
- CEO
- Liisa Hurme
- IPO
- 2014
- Employees
- 3,943
- HQ
- Espoo, FI
Price Chart
Valuation
- Market Cap
- $21.38B
- P/E
- 18.91
- P/S
- 5.13
- P/B
- 8.92
- EV/EBITDA
- 14.55
- Div Yield
- 2.42%
Profitability
- Gross Margin
- 64.79%
- Op Margin
- 34.11%
- Net Margin
- 27.12%
- ROE
- 48.73%
- ROIC
- 35.37%
Growth & Income
- Revenue
- $1.89B · 22.50%
- Net Income
- $480.55M · 45.67%
- EPS
- $0.86 · -27.23%
- Op Income
- $631.60M
- FCF YoY
- 6.15%
Performance & Tape
- 52W High
- $42.75
- 52W Low
- $30.89
- 50D MA
- $38.60
- 200D MA
- $37.91
- Beta
- 0.27
- Avg Volume
- 14
Get TickerSpark's AI analysis on ORINY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ORINY Coverage
We haven't published any research on ORINY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ORINY Report →